Cornerstone Investment Partners LLC Grows Holdings in Teva Pharmaceutical Industries Ltd (TEVA)

Cornerstone Investment Partners LLC lifted its stake in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 100.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 30,600 shares of the company’s stock after purchasing an additional 15,300 shares during the period. Cornerstone Investment Partners LLC’s holdings in Teva Pharmaceutical Industries were worth $580,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Capital Research Global Investors increased its position in shares of Teva Pharmaceutical Industries by 13.8% during the second quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock worth $2,535,518,000 after acquiring an additional 9,260,426 shares during the period. Northern Cross LLC increased its holdings in Teva Pharmaceutical Industries by 14.0% in the second quarter. Northern Cross LLC now owns 17,795,579 shares of the company’s stock valued at $591,169,000 after buying an additional 2,184,172 shares during the last quarter. Capital World Investors increased its holdings in Teva Pharmaceutical Industries by 41.9% in the second quarter. Capital World Investors now owns 11,068,200 shares of the company’s stock valued at $367,686,000 after buying an additional 3,268,200 shares during the last quarter. Schroder Investment Management Group increased its holdings in Teva Pharmaceutical Industries by 22.7% in the third quarter. Schroder Investment Management Group now owns 6,194,083 shares of the company’s stock valued at $106,290,000 after buying an additional 1,147,683 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. increased its holdings in Teva Pharmaceutical Industries by 4.5% in the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 6,035,644 shares of the company’s stock valued at $106,271,000 after buying an additional 259,891 shares during the last quarter. Hedge funds and other institutional investors own 51.93% of the company’s stock.

Several brokerages have issued reports on TEVA. Oppenheimer reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a research note on Thursday, February 8th. Maxim Group restated a “hold” rating on shares of Teva Pharmaceutical Industries in a research report on Thursday, February 8th. Cantor Fitzgerald set a $18.00 target price on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a report on Thursday, February 8th. Gabelli cut shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating and set a $19.00 price objective for the company. in a research note on Friday, February 9th. Finally, Leerink Swann dropped their price objective on shares of Teva Pharmaceutical Industries from $17.00 to $16.00 and set an “underperform” rating for the company in a research note on Friday, February 9th. Ten research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and seven have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $21.26.

Teva Pharmaceutical Industries Ltd (NYSE TEVA) traded up $0.81 during midday trading on Wednesday, reaching $19.33. 16,910,000 shares of the company’s stock traded hands, compared to its average volume of 20,170,000. Teva Pharmaceutical Industries Ltd has a 1 year low of $10.85 and a 1 year high of $37.94. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 1.20. The company has a market cap of $19,890.00, a PE ratio of -1.12, a price-to-earnings-growth ratio of 1.43 and a beta of 0.59.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Thursday, February 8th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.77 by $0.14. The firm had revenue of $5.46 billion during the quarter, compared to analysts’ expectations of $5.29 billion. Teva Pharmaceutical Industries had a negative net margin of 72.66% and a positive return on equity of 14.52%. Teva Pharmaceutical Industries’s quarterly revenue was down 15.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.38 EPS. equities research analysts anticipate that Teva Pharmaceutical Industries Ltd will post 2.69 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/14/teva-pharmaceutical-industries-ltd-teva-shares-bought-by-cornerstone-investment-partners-llc.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply